US OptionsDetailed Quotes

STRO241220P5000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayTrading Dec 16 09:30 ET
0.00High0.00Low

Sutro Biopharma Stock Discussion

Sign in to post a comment
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
    Tuesday, 10th December at 8:00 am
    - 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
    - These data confirm luvelta's robust response rate in patients with late-stage ovarian c...
    $Sutro Biopharma (STRO.US)$ Reuters· 2 mins ago
    Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
    Sutro Biopharma has initiated REFRαME-P1, a registration-enabling trial of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML. The study follows encouraging compassionate use data presented in December 2023, showing 42% complete remission in patients with ≥5% blasts. CBF/GLIS AML is a rare, aggressive leuke...
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
    Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory...
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
    Sutro Biopharma (NASDAQ: STRO) announced updated data from its Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for epithelial ovarian cancer (EOC) at ESMO 2024. Key findings include:
    - 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
    - 35% overal...
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
    Sutro Biopharma (NASDAQ: STRO) has initiated the REFRαME-L1 global Phase 2 study of luveltamab tazevibulin (luvelta) for non-small cell lung cancer (NSCLC)patients with Folate Receptor-α (FRα) expressing tumors.
    The trial is now open for enrollment, with initial data expected in H1 2025. Luvelta, an antibody drug conjugate (ADC), shows promise...
    $Sutro Biopharma (STRO.US)$ Reuters· just
    Sutro Biopharma Announces Initiation of RefrΑMe-L1 Phase 2 Trial With Luvelta for Patients With Non-Small Cell Lung Cancer
    $Sutro Biopharma (STRO.US)$ Sutro will present updated data from the Phase 1b study of luvelta in combination with bevacizumab for patients with ovarian cancer in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024 to be held September 13-17 in Barcelona, Spain.
    Title:  Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (b...
    $Sutro Biopharma (STRO.US)$ Completion of enrollment for Part One of the Phase II/III REFRaME-O1 trial for Luvelta and the anticipation of an update that could affirm its potential, which is estimated to be significantly greater than its competitor, Elahere, in platinum-resistant ovarian cancer (PROC). Bancroft highlights Luvelta’s ability to serve a wider PROC patient base, with the potential to address about 80% of patients expressing folate receptor alpha (FRα), in contr...
    4
    1
    $Sutro Biopharma (STRO.US)$ Sutro Biopharma Initiated at Buy by B of A Securities with a PT of 12.00!
    Dow Jones· 2 mins ago

No comment yet